FLT3 and acute myeloid leukemia: Therefore, the aim of our survey was to evaluate the management of FLT3‐mutated AML patients not included in clinical trials in Italy and, in addition, we aimed to assess during the period 2021–2023: (a) the proportion of patients receiving FLT3 inhibitors, (b) the efficacy (in terms of response rates) of FLT3 inhibitors, (c) the rate of AML patients discontinuing treatment due to intolerance or side effects, (d) the rate of early deaths, and (e) the rate of patients receiving FLT3 inhibitors as a bridge to allogeneic transplantation (hematopoietic stem cell transplantation (HSCT)).